Baxter drops as Q1 2026 earnings release hits tape on May 13
Baxter reported first-quarter 2026 results dated May 13, 2026, including a GAAP EPS loss of ($0.03) and adjusted EPS of $0.36. The same-day earnings release is a concrete catalyst that can plausibly explain the stock’s move.
1. What happened today (May 13, 2026)
Baxter published its first-quarter 2026 earnings results on May 13, 2026 (U.S. market day), which is a same-day, company-issued catalyst for the stock. The filing/release reports GAAP diluted EPS (loss) from continuing operations of ($0.03) and adjusted diluted EPS from continuing operations of $0.36.
2. Why it matters for the stock today
Quarterly results and any reaffirmed/updated full-year outlook can immediately reprice expectations for margins, cash flow, and leverage, especially for a large-cap medtech name with ongoing product and demand sensitivities. With the results landing today, market participants can directly react to reported profitability metrics and guidance framing rather than trading purely on technicals.
3. What to check next
To validate whether today’s -3.05% move is primarily earnings-driven, compare Baxter’s reported net sales and adjusted EPS to consensus estimates and scan the release deck for any changes to FY 2026 sales growth or adjusted EPS guidance. Also review any commentary on infusion pump/quality matters and tax/interest items that could affect near-term earnings power.